Opdivo Qvantig is the first subcutaneously administered PD-1 inhibitor approved by the FDA. It is expected to be available in ...

One of this year's top articles on cost and coverage highlights that the average American can afford a maximum of $97 in ...

Of the top news articles, Vertex Pharmaceuticals' suzetrigine garnered much attention as it's a promising new class of pain ...

Take a look at the best performing print articles of 2024. This year's top article spotlights the surge of mRNA vaccines ...

Anna Podolanczuk, M.D., M.S., discusses how key epidemiological trends in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), including changes in incidence and prevalence, ...

Historically, healthcare organizations have considered the contact center to be a cost center, a communications platform for ...

Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...

Gene therapies are revolutionizing treatment for hemophilia A and sickle cell disease; however, they are saddled with hefty ...

Up to half of obstructive sleep apnea patients taking Zepbound had no symptoms after one year of treatment, averaging 25 ...

Take a look at the best performing print articles of 2024. This year's top article spotlights the surge of mRNA vaccines ...

The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce ...

A new bill in Congress would require pass-through prices in both Medicare, and Medicaid and require transparency of PBM ...